Analysis of side effects during treatment with Imatinib (Gleevec)

Imatinib, also known as Gleevec, is a classic targeted drug mainly used to treat chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST). Since its introduction, imatinib has greatly improved the survival expectations and quality of life of patients with these diseases. However, like most anti-cancer drugs, imatinib may also cause a series of side effects during long-term treatment. Patients should be vigilant when taking the drug and cooperate with doctors for monitoring and management.

One of the most common side effects is digestive discomfort. Many patients experience nausea, vomiting, diarrhea, or abdominal bloating during the early stages of taking imatinib. These symptoms are usually mild, but may affect a patient's appetite and nutritional intake. In order to relieve discomfort, doctors usually recommend that patients take medicine after eating and swallow it with warm water. If necessary, they can use gastric mucosal protectants or antiemetic drugs to relieve symptoms. In addition, some patients may also experience oral ulcers or loss of appetite. Such reactions are more obvious in the early stages of medication and usually gradually lessen or disappear as the medication continues.

Myelosuppression is one of the important adverse reactions of imatinib, which requires more attention especially in the treatment of chronic myelogenous leukemia. Myelosuppression is manifested by a decrease in the count of white blood cells, red blood cells or platelets. Specific symptoms may include easy fatigue, pale complexion, easy bleeding or infection, etc. In order to detect such adverse reactions in time, patients should undergo routine blood tests regularly during medication. If low neutrophils or platelets are detected, doctors may pause the medication, adjust the dose, or intervene with drugs that promote blood cell production.

Imatinib may have certain effects on liver function. Some patients experience elevated liver enzymes (such as ALT, AST) during medication, and a few may even experience severe liver function damage. This reaction may occur early in treatment or during long-term use, so liver function needs to be monitored regularly. If symptoms such as jaundice, yellowing of the skin, darker urine, or obvious fatigue occur, you should seek medical attention promptly. In some cases, doctors may recommend a brief discontinuation of medication or the use of liver-protecting medications.

Edema and weight gain are also common adverse reactions, especially in the eyelids, ankles, and calves. Although this side effect is usually not serious, in some patients it can cause discomfort and even interfere with daily activities. The cause of edema may be related to the effect of imatinib on vascular permeability and renal function. At this point, your doctor may recommend reducing sodium intake and using mild diuretics if necessary to control symptoms. In addition, some patients will also report mild side effects such as rash, musculoskeletal pain, fatigue, and headache. These symptoms are mostly controllable reactions and usually do not affect continued medication.

Taken together, as a targeted drug, imatinib's side effects are generally controllable, and most patients can successfully complete treatment under standardized medication and doctor monitoring. In order to ensure the efficacy of the drug and reduce adverse reactions, patients should follow the doctor's advice to regularly check blood, liver and kidney function and weight changes, and also pay attention to life patterns and balanced diet. If obvious side effects occur, the doctor should be informed in time. It is not recommended to stop the medication or change the medication without authorization. In the future, with the continuous optimization of individualized treatment and drug management, the side effects of imatinib are expected to be further reduced, allowing more patients to achieve long-term survival on a safe basis.

Reference materials:https://www.gleevec.com/